Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves’ Orbitopathy

Figure 1

Treatment scheme. A0—patients with moderate-to-severe GO before treatment; A1—after administration of 0.5 g intravenous methylprednisolone (IVMP); A2—after administration of 3.0 g IVMP; A3—after administration of 4.5 g IVMP; B0—patients with DON before treatment; B1—after administration of 3.0 g IVMP; TSH—thyroid-stimulating hormone; fT3—free triiodothyronine; fT4—free thyroxine; aTPO—anti-thyroid peroxidase; aTG—thyroglobulin antibodies; TBII—thyroid-binding inhibitory immunoglobulin; AST—aspartate aminotransferase; ALT—alanine aminotransferase; HBs-Ag—hepatitis B surface antigen; HBs-Ab—hepatitis B surface antibody; HBc-Ab—hepatitis B core antibody; HCV-Ab—hepatitis C antibody; ANA—anti-nuclear antibodies; ASMA—anti-smooth muscle antibodies; AMA—anti-mitochondrial antibodies; anti-LKM—anti-liver kidney-microsomal antibodies; GO—Graves’ orbitopathy; DON—dysthyroid optic neuropathy.